Pharmacogenomics

Yui-wing F Lam, Larisa H. Cavallari

Research output: Book/ReportBook

6 Citations (Scopus)

Abstract

"Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation "includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics including academic, regulatory, economic, industry and medical to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics-including academic, regulatory, economic, industry and medical-to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research.

Original languageEnglish (US)
PublisherElsevier Inc.
ISBN (Print)9780123919182
DOIs
StatePublished - 2013

Fingerprint

Pharmacogenetics
Pharmaceutical Preparations
Medical Economics
Industry
Therapeutics
Economics
Research

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Lam, Y. F., & Cavallari, L. H. (2013). Pharmacogenomics. Elsevier Inc. https://doi.org/10.1016/C2010-0-69430-2

Pharmacogenomics. / Lam, Yui-wing F; Cavallari, Larisa H.

Elsevier Inc., 2013.

Research output: Book/ReportBook

Lam, Yui-wing F ; Cavallari, Larisa H. / Pharmacogenomics. Elsevier Inc., 2013.
@book{3b35f56aefce4d6f9a912036c96e3841,
title = "Pharmacogenomics",
abstract = "{"}Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation {"}includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics including academic, regulatory, economic, industry and medical to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics-including academic, regulatory, economic, industry and medical-to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research.",
author = "Lam, {Yui-wing F} and Cavallari, {Larisa H.}",
year = "2013",
doi = "10.1016/C2010-0-69430-2",
language = "English (US)",
isbn = "9780123919182",
publisher = "Elsevier Inc.",

}

TY - BOOK

T1 - Pharmacogenomics

AU - Lam, Yui-wing F

AU - Cavallari, Larisa H.

PY - 2013

Y1 - 2013

N2 - "Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation "includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics including academic, regulatory, economic, industry and medical to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics-including academic, regulatory, economic, industry and medical-to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research.

AB - "Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation "includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics including academic, regulatory, economic, industry and medical to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunities within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field. Provides perspectives from those involved in all aspects of pharmacogenomics-including academic, regulatory, economic, industry and medical-to illustrate how all of the pieces fit together and where the challenges may be. Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications. Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research.

UR - http://www.scopus.com/inward/record.url?scp=85013735601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013735601&partnerID=8YFLogxK

U2 - 10.1016/C2010-0-69430-2

DO - 10.1016/C2010-0-69430-2

M3 - Book

AN - SCOPUS:85013735601

SN - 9780123919182

BT - Pharmacogenomics

PB - Elsevier Inc.

ER -